Gossamer Bio Inc (GOSS) is trading 26% higher at $9.12 today. The stock rose on news that the company had raised $120 million in private equity financing. The stock was at the vanguard of a number of healthcare names including XORTX, Humanigen and Atara Biotherapeutics.

Gossamer Bio Inc has been trading between a 52-week high of $14.3 and a 52-week low of $5.64. The stock has a market cap of $703 Million.

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

Gossamer Bio Announces $120 Million Private Placement Financing
Business Wire 07-13-22

Gossamer Bio Upgraded to “Buy” by Zacks Investment Research
Business Mag 05-26-22

Gossamer Bio Inc. (GOSS) Has Strong Growth Prospects Through 2022
Marketing Sentinel 05-18-22